Medical Devices United States Bio-Pharma Market Report 2017 | Page 3

Report Description
Several manufacturers have tried to access the U.S. biopharma market for many years.
Recently, Celltrion, a South Korean based biopharma company has planned to ask for
approval for two more bio similar products from Foods and Drugs Administration (FDA).
Request sample report @ http://bit.ly/2sdcmZ3
Earlier, the firm has manufactured bio-similar copy of Remicade which was originally
manufactured by Johnson & Johnson has hit the US market in 2016. Of late, Celltrion has
claimed that it strategies to file Herzuma and Truxima which are in referenc to lymphatic
cancer drug by Roche in the name of Rituxan (rituximab) and breast cancer therapy Herceptin
(trastuzumab), respectively.
The firm anticipates that it would get permission by June 2017. Once the company gets
approval then its products which include Truxima and Herzuma would be sold in the US with
the help of Teva Pharmaceutical Industries, which is the largest producer of generic drugs in
the world.